studies

276A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
Scott L. Friedman - Advisory Committees or Review Panels: Pfizer Pharmaceutical;
Consulting: Conatus Pharm, Exalenz, Genfit, Exalenz Biosciences, Eli Lilly PHarmaceuticals,
Fibrogen, Boehringer Ingelheim, Nitto Corp., Immune Therapeutics,
Synageva, Roche/Genentech Pharmaceuticals, DeuteRx, Abbvie, Novartis,
RuiYi, Kinemed, Sanofi Aventis, Takeda Pharmaceuticals, Nimbus Therapeutics,
Bristol Myers Squibb, Astra Zeneca, Sandhill Medical Devices, Galmed, Northern
Biologics, Enanta Pharmaceuticals, Regado Bioscience, Raptor Pharmaceuticals,
Teva Pharmaceuticals, Zafgen Pharmaceuticals, Merck Pharmaceuticals,
Debio Pharmaceuticals; Grant/Research Support: Galectin Therapeutics, Tobira
Pharm; Stock Shareholder: Angion Biomedica, Intercept Pharma
John J. Sninsky - Consulting: Roche Diagnostics; Employment: CareDx
The following authors have nothing to disclose: Yuanqing Zhang, Lijun Peng,
Yirong Cao, Zhiping Zeng, Yujing Wu, Hong Shi, Shiyao Chen, Jiyao Wang,
Jinsheng Guo
132
Diabetes, HBV infection and smoking are independent
risk factors for developing hepatocellular carcinoma
on non-fibrotic liver in the NoFLIC French multicenter
case-control study.
Jean-Frédéric Blanc 1 , Adelaide Doussau 2 , Marie-Quitterie Picat 2 ,
Aline Maillard 2 , Caroline Bouyssou 1 , Charlotte E. Costentin 3 , Olivier
Rosmorduc 4 , Isabelle Rosa 5 , Luc Letenneur 2 , Karen Leffondre 6 ,
Jessica Zucman-Rossi 6 , Marianne Ziol 7 ; 1 Hepatology and Digestive
Oncology Unit, CHU bordeaux, Bordeaux, France; 2 ISPED,
Bordeaux, France; 3 Hepatology, Hopital Henri Mondor, Creteil,
France; 4 Heptology, Hopital saint-Antoine, Paris, France; 5 Hepatology,
CHI Créteil, Créteil, France; 6 INSERM U1162, Paris, France;
7 Pathologie, Hopital Jean Verdier, Bondy, France
risk factors for developing nfHCC. Conclusion NoFLIC is the
first case-control study dedicated to the study of factors associated
with the occurrence of HCC in non-fibrotic liver (F0/F1).
The first analysis shows a significant association between metabolic
syndrome, diabetes, HBV infection and smoking with the
occurrence of HCC in non-fibrotic liver suggesting an important
role of these factors in liver carcinogenesis.
Disclosures:
Jean-Frédéric Blanc - Advisory Committees or Review Panels: Lilly / Imclone,
Merck Serono, Sanofi; Speaking and Teaching: Bayer, BMS, Roche, Abbvie
Olivier Rosmorduc - Advisory Committees or Review Panels: Syrtex, IPSEN;
Speaking and Teaching: Bayer
Jessica Zucman-Rossi - Advisory Committees or Review Panels: Astellas, Celgene;
Consulting: Pfizer; Grant/Research Support: Integragen; Speaking and Teaching:
Bayer, Lilly
Marianne Ziol - Grant/Research Support: Echosens
The following authors have nothing to disclose: Adelaide Doussau, Marie-Quitterie
Picat, Aline Maillard, Caroline Bouyssou, Charlotte E. Costentin, Isabelle
Rosa, Luc Letenneur, Karen Leffondre
Introduction The occurrence of HCC in non-fibrotic liver (nfHCC)
is a rare event (5% of HCC patients) and factors contributing to
their onset remain poorly understood. The aim of the case-control
exploratory study NoFLIC was to identify factors involved
in hepatocarcinogenesis in non-fibrotic liver. Patients and
methods NoFLIC is a French multicenter case-control study that
included consecutive patients who developed HCC in a non-fibrotic
liver, F0 or F1, proven by histological analysis. Controls
were matched for age and gender, they were recruited in
people with gastro-intestinal screening and normal endoscopy,
or in rheumatology departments. Clinical data were collected
including the parameters of the metabolic syndrome defined
according to the NCEP-ATP3 criteria, viral serology, quantification
of alcohol and tobacco use. Data were taken from the
patient’s medical record, the results of blood test performed for
this study and a specific epidemiologic survey. Logistic regressions
adjusted for age, sex and geographical origin, were performed
to determine the association of each of the risk factors
with the status of the patient (case / control). A multivariate
analysis was performed to study the effect of significant risk
factors. Results A total of 109 nfHCC (cases) and 163 controls
were included in 12 hospitals between 2010 and 2013.
Mean age of the nfHCC patients was 64.4 years, with 68.8%
male. Active HBV infection was detected in 6 cases (OR 11.4,
95% 1.18-110.84, p=0.035). History of alcohol abuse was
more frequent in nfHCC (OR 2.13, 95% 1.09-4.16 p=0.026).
A metabolic syndrome was identified in 28% of the patients
developing nfHCC (OR 3.3; 95% CI 1.62-6.82 p=0.001).
Among the components of metabolic syndrome, treated diabetes
or fasting glucose ≥ 6.1mmol/l was significantly associated
with nfHCC occurrence (OR 3.08; 95% CI 1.67-5.69
p=0.0002), while there was no significant association with
BMI, hypertension and dyslipidemia. Smoking (defined by at
least 100 smoked cigarettes and at least with a weekly smoking
habit) was also associated with nfHCC (OR 2.18 adjusted
for age and sex; 95% CI 1.23-3.83 p = 0.0067). In multivariate
analysis, HBV infection (p=0.024), metabolic syndrome
(P=0.0023) and tobacco use (p=0.0062) were independent